0001127602-23-026187.txt : 20231024 0001127602-23-026187.hdr.sgml : 20231024 20231024161836 ACCESSION NUMBER: 0001127602-23-026187 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231023 FILED AS OF DATE: 20231024 DATE AS OF CHANGE: 20231024 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeLong Mark Jeffrey CENTRAL INDEX KEY: 0001856078 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 231342892 MAIL ADDRESS: STREET 1: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2023-10-23 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001856078 DeLong Mark Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Business & Strat Officer 0 Common Stock 2023-10-23 4 S 0 131 46.0362 D 51622 D This represents shares sold to cover tax withholding on a Restricted Stock Unit release. This includes 412 shares from 04/30/2023 ESPP purchase. /s/ David Watson, attorney-in-fact for Mark DeLong 2023-10-24